一个变化的范例：丙型肝炎病毒/艾滋病病毒合并感染患者的管理和治疗。
A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.
机构信息
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, MD, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
出版信息
Hepatol Int. 2018 Nov;12(6):500-509. doi: 10.1007/s12072-018-9896-4. Epub 2018 Sep 20.
Abstract
Hepatitis C virus (HCV) treatment in HIV/HCV co-infected individuals has renewed relevance given the ongoing opioid crisis and rise of new HIV and HCV infections associated with injection drug use. Patients co-infected with HIV and HCV demonstrate increased rates of hepatic fibrosis, progression to liver failure, and liver-related mortality. HIV co-infection does not impact outcomes of current HCV treatments, and patients should be treated the same as HCV mono-infected persons, though attention to drug:drug interactions is required. In this review, we discuss the mechanisms mediating injury to the liver in HIV mono-infection and HIV/HCV co-infection, and present the landmark trials of HCV treatment in HIV-infected individuals.
摘要
丙型肝炎病毒（HCV）治疗在 HIV/HCV 合并感染个体中具有新的意义，因为阿片类药物危机持续存在，以及与注射毒品使用相关的新的 HIV 和 HCV 感染不断增加。合并 HIV 和 HCV 感染的患者表现出更高的肝纤维化、肝衰竭进展和与肝脏相关的死亡率。HIV 合并感染并不影响目前 HCV 治疗的结果，并且患者应与 HCV 单一感染患者一样接受治疗，尽管需要注意药物相互作用。在这篇综述中，我们讨论了介导 HIV 单一感染和 HIV/HCV 合并感染中肝脏损伤的机制，并介绍了 HIV 感染者 HCV 治疗的里程碑式试验。
相似文献
1
A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.
Hepatol Int. 2018 Nov;12(6):500-509. doi: 10.1007/s12072-018-9896-4. Epub 2018 Sep 20.
2
HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.
PLoS One. 2012;7(11):e50289. doi: 10.1371/journal.pone.0050289. Epub 2012 Nov 30.
3
Current treatment options for hepatitis C patients co-infected with HIV.
Expert Rev Gastroenterol Hepatol. 2016 Jun;10(6):689-95. doi: 10.1586/17474124.2016.1145545. Epub 2016 Feb 12.
4
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Int J Infect Dis. 2017 Sep;62:64-71. doi: 10.1016/j.ijid.2017.07.001. Epub 2017 Jul 17.
5
Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
Liver Int. 2015 Jan;35 Suppl 1:51-5. doi: 10.1111/liv.12721.
6
Optimum combination therapy regimens for HIV/HCV infection.
Expert Rev Anti Infect Ther. 2016;14(3):299-309. doi: 10.1586/14787210.2016.1147952.
7
Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients.
J Clin Gastroenterol. 2014 Feb;48(2):106-12. doi: 10.1097/MCG.0000000000000010.
8
Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection.
Expert Rev Clin Pharmacol. 2014 Nov;7(6):691-704. doi: 10.1586/17512433.2014.956091. Epub 2014 Sep 11.
9
HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
BMC Infect Dis. 2016 Dec 12;16(1):755. doi: 10.1186/s12879-016-2089-7.
10
Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects.
Viruses. 2022 Jul 22;14(8):1594. doi: 10.3390/v14081594.
引用本文的文献
1
Rapid simultaneous self-testing of HIV and HCV viral loads with integrated RNA extraction and multiplex RT-PCR in under 1 hour.
Biosens Bioelectron. 2025 Aug 2:117843. doi: 10.1016/j.bios.2025.117843.
2
Toxoplasma gondii, HBV, and HCV co-infection and their correlation with CD4 cells among Iranian HIV-positive patients.
Immun Inflamm Dis. 2023 Feb;11(2):e794. doi: 10.1002/iid3.794.
3
Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?
Viruses. 2021 Jun 1;13(6):1048. doi: 10.3390/v13061048.
4
Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus.
Health Qual Life Outcomes. 2021 May 26;19(1):154. doi: 10.1186/s12955-021-01777-x.
5
Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study.
Front Med (Lausanne). 2021 Feb 1;8:615342. doi: 10.3389/fmed.2021.615342. eCollection 2021.
6
Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study.
Sci Rep. 2020 Jun 25;10(1):10384. doi: 10.1038/s41598-020-67159-3.
7
Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus.
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00773-20.
8
Innate Immunity in Hepatitis C Virus Infection.
Cold Spring Harb Perspect Med. 2021 Feb 1;11(2):a036988. doi: 10.1101/cshperspect.a036988.
9
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
PLoS One. 2020 Feb 13;15(2):e0228847. doi: 10.1371/journal.pone.0228847. eCollection 2020.
本文引用的文献
1
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.
Hepatol Int. 2018 May;12(3):214-222. doi: 10.1007/s12072-018-9873-y. Epub 2018 May 29.
2
The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Drug Metab Dispos. 2018 Aug;46(8):1212-1225. doi: 10.1124/dmd.117.079038. Epub 2018 Apr 25.
3
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417.
4
Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study.
J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):438-444. doi: 10.1097/QAI.0000000000001524.
5
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Int J Infect Dis. 2017 Sep;62:64-71. doi: 10.1016/j.ijid.2017.07.001. Epub 2017 Jul 17.
6
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
Clin Infect Dis. 2017 Jul 1;65(1):6-12. doi: 10.1093/cid/cix260.
7
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
J Infect Dis. 2017 Feb 15;215(4):599-605. doi: 10.1093/infdis/jiw597.
8
Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV.
HIV Med. 2017 Oct;18(9):685-689. doi: 10.1111/hiv.12502. Epub 2017 Feb 23.
9
Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
Pathog Glob Health. 2016 Oct-Dec;110(7-8):310-315. doi: 10.1080/20477724.2016.1253532. Epub 2016 Nov 10.
10
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.
Clin Infect Dis. 2016 Nov 1;63(9):1160-1167. doi: 10.1093/cid/ciw531. Epub 2016 Aug 9.
Zotero 插件